I’ve written about PARP inhibitors recently, but they’re back in the news.
Patients with cancer genes—BRCA1 and BRCA2—have been shown to react positively to a type of PARP inhibitor, a drug called olaparib. In a small but significant study, olaparib was successful in shrinking breast and prostate cancer tumors, with some disappearing entirely. The study was reported in the New England Journal of Medicine.
Read more about it here.
PARP is short for poly (ADP-ribose) polymerase, an enzyme used by cancer cells to repair DNA damage.